Core Insights - Novo Nordisk announced the official launch of injectable pegylated recombinant factor VIII (brand name: Nuwiq®) in mainland China, marking it as the only long-acting recombinant factor VIII approved in the country [1] - Nuwiq® has been added to the new national medical insurance catalog, enhancing accessibility for patients with Hemophilia A and ushering them into a new treatment phase [1] Group 1: Product and Market Impact - Nuwiq® fills a significant gap in long-term treatment for Hemophilia A in China, which affects approximately 80%-85% of all hemophilia patients [1] - The product's launch is expected to improve medication accessibility for patients, who require lifelong treatment to avoid severe health risks [1] Group 2: Clinical Data and Efficacy - Since its approval in the U.S. in 2019, Nuwiq® has accumulated extensive efficacy and safety data for the prevention and treatment of bleeding globally [1] - In a multi-center trial (Pathfinder10) conducted among Chinese Hemophilia A patients, the median annualized bleeding rate (ABR) for those receiving preventive treatment with Nuwiq® was 0.00, with 69.4% of patients experiencing zero bleeding events and a 94.8% success rate in stopping bleeding [1]

Core Insights - The company reported a total operating revenue of 31.629 billion yuan for the year 2025, representing a year-on-year growth of 14.53% [1] - The net profit attributable to shareholders of the listed company reached 3.422 billion yuan, with a year-on-year increase of 1.60% [1] Strategic Focus - The company aims to adhere to a dual-driven strategy of "innovation + brand" to navigate a complex market environment [1] - The focus is on core treatment areas, expanding the research and development pipeline from multiple dimensions to uncover innovative value [1] - The company is committed to enhancing brand advantages, optimizing business layout, and forging a competitive edge across the entire industry chain to solidify its leading position in the industry [1] - The strategic goal is to strive to become a top enterprise in the industry [1]

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 | | 主要股东 | | 俞德超(5.36%) | | 每股净值(港币) | | 9.8324 | | 股价/帐面净值 | | 8.0855 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -10.97 -6.69 139.82 | | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% ...

Core Viewpoint - Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of Zhongguancun (000931.SZ), has received approval from the National Medical Products Administration for its drug "Tramadol Hydrochloride Tablets" (specification: 50mg), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a key milestone for Beijing Huasu in the pharmaceutical market [1] - The drug "Tramadol Hydrochloride Tablets" is now positioned to compete effectively in the generic drug sector [1] - This development may enhance the company's revenue potential and market share in the pain management segment [1]

远程医疗企业Hims & Hers周末因受到诺和诺德的法律追责及美国食品药品监督管理局的相关警告，宣 布搁置其49美元复方减肥丸的上市计划，受此消息影响，诺和诺德在法兰克福上市的股票周一上涨 4.5%。 Hims & Hers上周四推出了这款减肥丸，其核心成分为司美格鲁肽——这也是诺和诺德爆款药物司美格 鲁肽减肥针和司美格鲁肽降糖针的关键原料，此举随即引发这家丹麦制药企业及监管机构的反对。周 六，Hims & Hers表示，在与相关利益方进行"建设性沟通"后，将停止提供该款减肥产品。 此前美国食药监局局长马蒂・马卡里已表态将严厉打击未经批准的胰高血糖素样肽-1类复方药物，这类 药物对诺和诺德在减肥和糖尿病市场的定价权形成了冲击，受该表态影响，诺和诺德股价上周五已反弹 超5%。 此前美国食药监局局长马蒂・马卡里已表态将严厉打击未经批准的胰高血糖素样肽-1类复方药物，这类 药物对诺和诺德在减肥和糖尿病市场的定价权形成了冲击，受该表态影响，诺和诺德股价上周五已反弹 超5%。 尽管此次股价再度走高，诺和诺德仍面临巨大的经营压力，一方面要应对礼来公司的市场竞争，另一方 面还要直面价格更低的复方替代药冲击。该公司在上周发 ...

Core Viewpoint - Beijing Huasu Pharmaceutical, a subsidiary of Zhongguancun, has received notification from the National Medical Products Administration that its product "Tramadol Hydrochloride Tablets" (50mg) has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1: Company Developments - Beijing Huasu is the fourth company to pass the consistency evaluation, joining three other companies that have already received approval [1] - The project has incurred a total research and development cost of approximately 5.9 million yuan [1] Group 2: Market Impact - The successful evaluation is expected to enhance the competitiveness of the drug and positively impact the company's performance [1] - However, drug sales are influenced by various factors, leading to inherent uncertainties [1]

Core Viewpoint - The company has received a drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new hypertension treatment [1] Group 1: Company Information - The drug is named Candesartan Cilexetil Tablets, with a dosage form of tablets and a specification of 16mg [1] - The registration classification of the drug is categorized as a Class 4 chemical drug [1] Group 2: Industry Relevance - The drug is indicated for the treatment of primary hypertension, which is a significant area in the pharmaceutical industry given the prevalence of hypertension globally [1]

南方医科大学南方医院孙竞教授表示，标准重组凝血因子(SHL-rFⅧ)输注频率高，治疗依从性差。如应 用其规律性替代治疗，其谷浓度(给药期间的最低浓度)不能始终大于1%，突破性出血风险高，残疾率 高。诺易特通过创新结构修饰，将凝血因子Ⅷ半衰期延长至19小时，较标准制剂提升1.6倍，可减少 50%-71%的静脉注射次数，同时按说明书指导剂量使用，可将谷值改善至平均3%，降低患者注射负担 及关节出血的风险，尤其适配青少年低注射频率及高运动量的需求，显著提升治疗依从性。 血友病是一种X染色体连锁的隐性遗传性出血性疾病，可分为血友病A和血友病B两种。其中，血友病A 为凝血因子Ⅷ(FⅧ)缺乏，其患者约占所有血友病患者中的80%-85%，需终身用药，如不及时治疗，会 导致残疾，严重时甚至危及生命。随着治疗手段的不断进步，研究显示，越来越多患者期待长效凝血因 子降低注射次数。 新京报讯(记者王卡拉)近日，诺和诺德宣布，注射用培妥罗凝血素α(商品名：诺易特)在中国大陆正式上 市。诺易特是我国首个且目前唯一获批的长效重组凝血因子Ⅷ，且已成功被新版国家医保目录新增纳 入。诺易特适用于12岁及以上血友病A(先天性凝血因子Ⅷ缺乏)患者 ...

Core Viewpoint - The article emphasizes the cyclical nature of fortune and misfortune, illustrating how crises can lead to opportunities through strategic decision-making and adaptability in business contexts [4][5]. Group 1: Application of Wisdom in Business - The principle of "反者道之动，弱者道之用" (the movement of opposites and the use of the weak) is applicable in investment and business management, suggesting that understanding the dynamics of fortune and misfortune can guide effective decision-making [6]. - The case of Johnson & Johnson's Tylenol crisis in 1982 demonstrates how proactive and transparent communication, along with decisive action, can restore consumer trust and market share after a significant setback [9][11]. - Johnson & Johnson's CEO James Burke made bold decisions, including a global recall of 31 million bottles of Tylenol, which resulted in a direct loss of $100 million but ultimately led to a recovery of market share to 30% within a year [9][12]. Group 2: Historical Context and Market Reactions - The article recounts the historical context of the British stock market during World War II, highlighting a significant rebound after a steep decline, illustrating that market recovery can occur even in dire circumstances [15][17]. - The stock market's recovery was attributed to a shift in public sentiment, where the realization that conditions could not worsen led to renewed optimism [17][20]. - The concept of "祸" (misfortune) and "福" (fortune) being interdependent is reinforced through historical examples, indicating that strategic responses to crises can lead to positive outcomes [20]. Group 3: Lessons from Investment Failures - The article warns against the dangers of "catching falling knives" in investment, as exemplified by Bill Miller's significant losses during the 2008 financial crisis when he invested in failing financial institutions [21][22]. - Understanding the principle of "反者道之动，弱者道之用" could have helped investors like Miller avoid substantial losses by recognizing the risks associated with market downturns [23].

Investment Rating - The investment rating for the company is upgraded to "Outperform" [2][8]. Core Insights - The company reported a revenue of 1.058 billion yuan for 2025, representing a year-on-year growth of 21.8%, and a net profit of 237 million yuan, up 33.9% year-on-year. The fourth quarter of 2025 saw revenues of 262 million yuan, a 21.5% increase, and a net profit of 78 million yuan, up 26.4% year-on-year [5][8]. - The company is expanding its generic drug product line while simultaneously advancing new drug development. The fourth quarter profits exceeded expectations due to delayed large R&D expenditures and effective cost reduction measures [5][8]. - The company is actively increasing its pipeline of innovative drugs, with the DYX116 project progressing as expected. The drug has completed Phase I clinical trials and is set to enter Phase II trials in the first half of 2026 [8]. Financial Data and Profit Forecast - The total revenue forecast for 2025 is 1.058 billion yuan, with a projected growth rate of 21.8%. The net profit for 2025 is estimated at 237 million yuan, with a growth rate of 33.9% [7][11]. - The company’s projected net profits for 2025, 2026, and 2027 are 237 million yuan, 174 million yuan, and 140 million yuan respectively, reflecting a downward adjustment for 2026 and 2027 due to anticipated price reductions from centralized procurement [8][9]. - The company’s price-to-earnings (PE) ratios for 2025, 2026, and 2027 are projected at 18, 24, and 30 respectively, compared to an average PE of 38 for comparable companies [9][8].